About
Senzime AB is a Swedish medical technology company specializing in the development, production, and marketing of products for monitoring the neuromuscular blockade state and preventing postoperative complications in patients. Founded in 2013, Senzime has become a major provider of medical devices on the global market. Its business model revolves around designing and producing intelligent monitoring devices that allow healthcare professionals to control important patient parameters during anesthesia and the postoperative phase. Senzime has developed various products for monitoring the neuromuscular blockade state, early detection of postoperative complications, and specialized use in intensive care medicine. The company is focused on continuous innovation and collaboration with healthcare professionals, universities, and research institutions to improve its technology and applications. Senzime aims to enhance patient safety and make treatment more effective and secure.
Annual results
Reported figures, SEK · revenue up 79.3% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 104M | -137M | -131.7% | — |
| 2024 | 58.0M | -118M | -203.4% | — |
| 2023 | 35.0M | -134M | -382.9% | — |
| 2022 | 14.0M | -132M | -942.9% | — |
| 2021 | 10.0M | -82.0M | -820.0% | — |
SEZI.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Senzime AB (publ) are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.